Baxter (BAX) Healthcare Announces Licensing Agreement with Innocoll for Gentamicin Surgical Implant
Down)
Baxter (NYSE: BAX) Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, granting Baxter exclusive rights to market and distribute the company's gentamicin surgical implant in the United States.
The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections in the United States. This agreement is expected to add to Baxter's biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post-operative complications of SSIs during surgery.
Baxter International, Inc. operates as a healthcare company worldwide.
The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections in the United States. This agreement is expected to add to Baxter's biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post-operative complications of SSIs during surgery.
Baxter International, Inc. operates as a healthcare company worldwide.
You May Also Be Interested In
- Baxter to Present at Goldman Sachs 33rd Annual Global Healthcare Conference
- Dynasil (DYSL) Shares Halted Again Immediately Upon Resumption, Now Up 74%; Co. Enters Tech Pact with Mayo Clinic
- Watson Pharma (WPI) Confirms Patent Challenge on Testim from Auxilium
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
